

L Number	Hits	Search Text	DB	Time stamp
1	3331	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:06
2	7	(Dean near2 Irwin).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:58
3	1649	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:07
4	565	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:09
5	139	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:11
7	35	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:18
8	35	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:57
9	1	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and (minimal adj erythema adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:40
10	5	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and ('MED' or (minimal adj erythema adj dose)) and (vitiligo psoriasis melanoma)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:05
12	5	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and (vitiligo psoriasis melanoma) and ((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:06

6	25	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet))) and (cool\$4 same (tissue\$1 or skin))) and (vitiligo psoriasis melanoma)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:13
13	25	(US-4733660-\$ or US-5312395-\$ or US-5620478-\$ or US-5626631-\$ or US-5720772-\$ or US-5755751-\$ or US-5836999-\$ or US-5843143-\$ or US-5989283-\$ or US-6017360-\$ or US-6050990-\$ or US-6149671-\$ or US-6171332-\$ or US-6214034-\$ or US-6269818-\$ or US-6280438-\$ or US-6283956-\$ or US-6290712-\$ or US-6290713-\$).did. or (US-20020161418-\$ or US-20020173780-\$ or US-20020173833-\$ or US-20030004499-\$ or US-20030004556-\$ or US-20030069567-\$).did.	USPAT; US-PGPUB	2003/08/19 12:57
17	3229	Irwin.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:58
18	2	((Dean near2 Irwin).in.) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:04
19	0	((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and Irwin.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:03
20	0	Irwin.in. and (minimal adj erythema adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:04
21	1	((US-4733660-\$ or US-5312395-\$ or US-5620478-\$ or US-5626631-\$ or US-5720772-\$ or US-5755751-\$ or US-5836999-\$ or US-5843143-\$ or US-5989283-\$ or US-6017360-\$ or US-6050990-\$ or US-6149671-\$ or US-6171332-\$ or US-6214034-\$ or US-6269818-\$ or US-6280438-\$ or US-6283956-\$ or US-6290712-\$ or US-6290713-\$).did. or (US-20020161418-\$ or US-20020173780-\$ or US-20020173833-\$ or US-20030004499-\$ or US-20030004556-\$ or US-20030069567-\$).did.) and (minimal adj erythema adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:05
14	5	((US-4733660-\$ or US-5312395-\$ or US-5620478-\$ or US-5626631-\$ or US-5720772-\$ or US-5755751-\$ or US-5836999-\$ or US-5843143-\$ or US-5989283-\$ or US-6017360-\$ or US-6050990-\$ or US-6149671-\$ or US-6171332-\$ or US-6214034-\$ or US-6269818-\$ or US-6280438-\$ or US-6283956-\$ or US-6290712-\$ or US-6290713-\$).did. or (US-20020161418-\$ or US-20020173780-\$ or US-20020173833-\$ or US-20030004499-\$ or US-20030004556-\$ or US-20030069567-\$).did.) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:12
25	28	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)) and (vitiligo psoriasis melanoma)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:11

26	1	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)) and (vitiligo psoriasis melanoma)) and (minimal adj erythema adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:15
28	2	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)) and (vitiligo psoriasis melanoma)) and (minimal adj erythema\$1 adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:16
29	5	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (minimal adj erythema\$1 adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:20
30	5	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (minimal adj erythema\$1 adj dose)) and ('UV' 'UVB' 'UVA')	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:20
31	2	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (minimal adj erythema\$1 adj dose)) and ('UV' 'UVB' 'UVA')) and cool\$4	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:21
32	7	((("5595568") or ("5653706") or ("6059820") or ("5830208") or ("5820626") or ("5057104") or ("6083218")).PN.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:40
33	2	((("5595568") or ("5653706") or ("6059820") or ("5830208") or ("5820626") or ("5057104") or ("6083218")).PN.) and ('UV' or ultraviolet or (ultra adj violet))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:44
34	5	((("5595568") or ("5653706") or ("6059820") or ("5830208") or ("5820626") or ("5057104") or ("6083218")).PN.) not (((("5595568") or ("5653706") or ("6059820") or ("5830208") or ("5820626") or ("5057104") or ("6083218")).PN.) and ('UV' or ultraviolet or (ultra adj violet)))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 14:02
-	275	(606/9).CCLS.	USPAT	2002/07/29 15:26
-	17	((606/9).CCLS.) and (excimer adj laser)	USPAT	2002/07/29 20:55
-	37	((606/9).CCLS.) and 'UV'	USPAT	2002/07/29 15:29
-	7	(Dean near2 Irwin).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/18 15:11
-	7	(Dean near2 Irwin).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:06
-	3323	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:06
-	1643	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:06
-	394	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:07

-	177	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:09
-	28	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)) and (vitiligo psoriasis melanoma)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:10

	1	Document ID	Title	Current OR
1	<input checked="" type="checkbox"/>	US 6280438 B1	Method and apparatus for electromagnetic treatment of the skin, including hair	606/9
2	<input checked="" type="checkbox"/>	WO 2055149 A2	CONTROLLED DOSE DELIVERY OF ULTRAVIOLET LIGHT FOR TREATING SKIN DISORDERS	
3	<input checked="" type="checkbox"/>	US 20020183811 A1	Treatment of skin disorders with UV light and cooling	607/94
4	<input checked="" type="checkbox"/>	US 6514243 B1	Method and apparatus for electromagnetic treatment of the skin, including hair	606/9
5	<input checked="" type="checkbox"/>	US 6447537 B1	Targeted UV phototherapy apparatus and method	607/94
6	<input checked="" type="checkbox"/>	US 6413268 B1	Apparatus and method for targeted UV phototherapy of skin disorders	607/94
7	<input checked="" type="checkbox"/>	US 6214034 B1	Method of selective photothermolysis	607/89
8	<input checked="" type="checkbox"/>	US 6171332 B1	Light source	607/89
9	<input checked="" type="checkbox"/>	US 5836999 A	Method and apparatus for treating psoriasis using pulsed electromagnetic radiation	607/88
10	<input checked="" type="checkbox"/>	US 5755751 A	Method and apparatus for therapeutic electromagnetic	607/88
11	<input checked="" type="checkbox"/>	US 6142939 A	Microporation of human skin for drug delivery and monitoring applications	600/309
12	<input checked="" type="checkbox"/>	US 6120497 A	Method and apparatus for treating wrinkles in skin using radiation	606/9

	Inventor
1	Eckhouse, Shimon et al.
2	IRWIN, DEAN S
3	Irwin, Dean S.
4	Eckhouse, Shimon et al.
5	Hartman, Raymond A.
6	Hartman, Raymond A.
7	Azar, Zion
8	Whitehurst, Colin
9	Eckhouse, Shimon et al.
10	Eckhouse, Shimon
11	Eppstein, Jonathan A. et al.
12	Anderson, R. Rox et al.

	1	Document ID	Title	Current OR
13	<input checked="" type="checkbox"/>	US 6017360 A	Skin light exposure control methods	607/88
14	<input checked="" type="checkbox"/>	US 6050990 A	Methods and devices for inhibiting hair growth and related skin treatments	606/9
15	<input checked="" type="checkbox"/>	US 4733660 A	Laser system for providing target specific energy deposition and damage	606/9
16	<input checked="" type="checkbox"/>	US RE36634 E	Optical system for treatment of vascular lesions	606/9
17	<input type="checkbox"/>	US 4978952 A	Flat screen color video display	345/102
18	<input checked="" type="checkbox"/>	US 6436127 B1	Phototherapy methods and systems	607/89

	Inventor
13	Chubb, Charles R. et al.
14	Tankovich, Nikolai I. et al.
15	Itzkan, Irving
16	Ghaffari, Shahriar
17	Irwin, Dean S.
18	Anderson, Richard Rox et al.

L Number	Hits	Search Text	DB	Time stamp
1	3331	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:06
2	7	(Dean near2 Irwin).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:58
3	1649	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:07
4	565	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:09
5	139	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:11
7	35	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:18
8	35	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:57
9	1	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and (minimal adj erythema adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:40
10	5	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and ('MED' or (minimal adj erythema adj dose)) and (vitiligo psoriasis melanoma)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:05
12	5	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and (vitiligo psoriasis melanoma) and ((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:06
6	25	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue)) and ((Excimer adj laser\$1) or 'UV' or ultraviolet or (ultra adj violet)) and (cool\$4 same (tissue\$1 or skin)) and (vitiligo psoriasis melanoma)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:13

13	25	(US-4733660-\$ or US-5312395-\$ or US-5620478-\$ or US-5626631-\$ or US-5720772-\$ or US-5755751-\$ or US-5836999-\$ or US-5843143-\$ or US-5989283-\$ or US-6017360-\$ or US-6050990-\$ or US-6149671-\$ or US-6171332-\$ or US-6214034-\$ or US-6269818-\$ or US-6280438-\$ or US-6283956-\$ or US-6290712-\$ or US-6290713-\$).did. or (US-20020161418-\$ or US-20020173780-\$ or US-20020173833-\$ or US-20030004499-\$ or US-20030004556-\$ or US-20030069567-\$).did.	USPAT; US-PGPUB	2003/08/19 12:57
17	3229	Irwin.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 12:58
18	2	((Dean near2 Irwin).in.) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:04
19	0	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and Irwin.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:03
20	0	Irwin.in. and (minimal adj erythema adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:04
21	1	((US-4733660-\$ or US-5312395-\$ or US-5620478-\$ or US-5626631-\$ or US-5720772-\$ or US-5755751-\$ or US-5836999-\$ or US-5843143-\$ or US-5989283-\$ or US-6017360-\$ or US-6050990-\$ or US-6149671-\$ or US-6171332-\$ or US-6214034-\$ or US-6269818-\$ or US-6280438-\$ or US-6283956-\$ or US-6290712-\$ or US-6290713-\$).did. or (US-20020161418-\$ or US-20020173780-\$ or US-20020173833-\$ or US-20030004499-\$ or US-20030004556-\$ or US-20030069567-\$).did.) and (minimal adj erythema adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:05
14	5	((US-4733660-\$ or US-5312395-\$ or US-5620478-\$ or US-5626631-\$ or US-5720772-\$ or US-5755751-\$ or US-5836999-\$ or US-5843143-\$ or US-5989283-\$ or US-6017360-\$ or US-6050990-\$ or US-6149671-\$ or US-6171332-\$ or US-6214034-\$ or US-6269818-\$ or US-6280438-\$ or US-6283956-\$ or US-6290712-\$ or US-6290713-\$).did. or (US-20020161418-\$ or US-20020173780-\$ or US-20020173833-\$ or US-20030004499-\$ or US-20030004556-\$ or US-20030069567-\$).did.) and ('MED' or (minimal adj erythema adj dose))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:12
25	28	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)) and (vitiligo psoriasis melanoma)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:11
26	1	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)) and (vitiligo psoriasis melanoma)) and (minimal adj erythema adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:15

28	2	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)) and (vitiligo psoriasis melanoma)) and (minimal adj erythema\$1 adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:16
29	5	((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (minimal adj erythema\$1 adj dose)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:20
30	5	((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (minimal adj erythema\$1 adj dose)) and ('UV' 'UVB' 'UVA')	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:20
31	2	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (minimal adj erythema\$1 adj dose)) and ('UV' 'UVB' 'UVA')) and cool\$4	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:21
32	7	((("5595568") or ("5653706") or ("6059820") or ("5830208") or ("5820626") or ("5057104") or ("6083218")).PN.	USPAT	2003/08/19 13:40
33	2	((("5595568") or ("5653706") or ("6059820") or ("5830208") or ("5820626") or ("5057104") or ("6083218")).PN.) and ('UV' or ultraviolet or (ultra adj violet))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:44
34	5	((("5595568") or ("5653706") or ("6059820") or ("5830208") or ("5820626") or ("5057104") or ("6083218")).PN.) not (((("5595568") or ("5653706") or ("6059820") or ("5830208") or ("5820626") or ("5057104") or ("6083218")).PN.) and ('UV' or ultraviolet or (ultra adj violet)))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 13:45
-	275	(606/9).CCLS.	USPAT	2002/07/29 15:26
-	17	((606/9).CCLS.) and (excimer adj laser)	USPAT	2002/07/29 20:55
-	37	((606/9).CCLS.) and 'UV'	USPAT	2002/07/29 15:29
-	7	(Dean near2 Irwin).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/18 15:11
-	7	(Dean near2 Irwin).in.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:06
-	3323	((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:06
-	1643	((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:06
-	394	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV'))	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:07
-	177	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM_TDB	2003/08/19 11:09

-	28	(((((606/3,8-11,13,16-18,20,22,23,25,26) or (607/88-91)).CCLS.) and (treat\$5 same (skin tissue))) and ((Excimer adj laser\$1) or 'UV')) and (cool\$4)) and (vitiligo psoriasis melanoma)	USPAT; US-PGPUB; EPO; JPO; DERWENT; IBM TDB	2003/08/19 13:10
---	----	---	---	------------------

- **Surgilight Inc. (SRGL) Licenses Excimer Laser Technology To RA Medical Systems, In Vitiligo Applications**

ORLANDO, Fla., March 18 /PRNewswire-FirstCall/ -- **SurgiLight**, Inc. (OTC Bulletin Board: SRGL), a leader in excimer laser systems, today announced that it has granted an exclusive three-year license for its EX-308 Excimer laser technology to Carlsbad, CA-based RA Medical Systems, Inc., a privately held developer, manufacturer and marketer of excimer laser systems for treatment of various medical conditions. RA Medical anticipates the introduction of its PHAROS EX-308, Excimer laser system for treatment by dermatologists of psoriasis and **vitiligo** (pigmentation loss) this summer. The FDA had earlier cleared the technology itself for treatment of those two disorders which, according to national advocacy organizations, affect over 11 million Americans. Psoriasis alone accounts for more than 250,000 new cases annually in the U.S.

(See Story from BioSpace.com) (3/18/03)

This is Google's cache of <http://www.epiprensa.com/estetica/mediform.htm>.

Google's cache is the snapshot that we took of the page as we crawled the web.

The page may have changed since that time. Click here for the [current page](#) without highlighting.

To link to or bookmark this page, use the following url: [http://www.google.com/search?](http://www.google.com/search?q=cache:UHR2SSOJrX4J:www.epiprensa.com/estetica/mediform.htm+SurgiLight+vitiligo+OR+XeCl+OR+cool+OR+cooling&18)

[q=cache:UHR2SSOJrX4J:www.epiprensa.com/estetica/mediform.htm+SurgiLight+vitiligo+OR+XeCl+OR+cool+OR+cooling&18](http://www.google.com/search?q=cache:UHR2SSOJrX4J:www.epiprensa.com/estetica/mediform.htm+SurgiLight+vitiligo+OR+XeCl+OR+cool+OR+cooling&18)

Google is not affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **surgilight vitiligo**



Pioneros en Dermocosmética

Con unos inicios que datan del año 1988, de la mano de su fundador, el Sr. Josep Colls, el Grupo Mediform se crea con el objetivo de introducir en España las principales novedades tecnológicas en dermocosmética, dirigidas a dermatólogos, flebólogos y cirujanos plásticos, estéticos y reparadores.

En la actualidad, el Grupo Mediform se encuentra integrado por dos compañías principales: Surgiform, dedicada a la distribución de consumibles tales como prótesis mamarias, endoprótesis inyectables o peelings, y **Surgilight**, especializada en aparatología con base de tecnología láser e IPL (Luz Intensa Pulsada).

Presente en toda España y, desde hace un año, implantado también en Portugal, con oficinas en Madrid, Barcelona, Málaga y Lisboa, Mediform es un grupo de empresas sólidamente implantado en el sector de la dermocosmética, que ha basado su excelente trayectoria en la introducción continuada de nuevas e innovadoras



soluciones de firmas punteras a nivel internacional, que apuestan fuertemente por la investigación y el desarrollo de nuevos productos.



Prueba de ello es que, en 1997, Mediform fue responsable de la introducción de la fotodepilación con luz pulsada en España. En 1998 se introducía el Resurfacing con Erbio Yag, menos invasivo que otras técnicas ya existentes y, sólo un año después, se presentaba el Vasculight, un equipo láser para el tratamiento de las varices de las piernas. Durante el pasado año 2001 se introdujo la fototerapia del acné y un tratamiento no invasivo de fotorejuvenecimiento y, durante el 30º Congreso de Dermatología, celebrado en Madrid el pasado mes de mayo, se dio a conocer un nuevo equipo de fototerapia para el tratamiento de la psoriasis localizada y el **vitiligo**.

Esta voluntad pionera de Mediform se ve respaldada por un departamento médico, integrado por tres médicos especialistas propios, encargados de llevar a cabo todo el asesoramiento y la formación necesaria sobre los equipos en la propia clínica del cliente. Asimismo, en su voluntad por difundir todo lo relacionado con esta actividad, Mediform lleva ya cuatro años organizando Jornadas Internacionales en Láser, Luz Intensa Pulsada y Técnicas Dermocosméticas, cuya cuarta edición reunió a más de 600 médicos asistentes y 41 conferenciantes nacionales e internacionales durante el pasado mes de noviembre en Madrid.

Siempre en continua evolución, la división intervencionista de Mediform introdujo el año pasado, la criocirugía para erradicar el cáncer de próstata. El primer equipo fue utilizado por el Dr. Banús en la Clínica del Pilar de Barcelona. En estos meses van a instalarse nuevos equipos en 4 clínicas más. Se trata de un procedimiento que permite al paciente reincorporarse a su actividad normal a las 24 horas de su intervención y que se convierte en una excelente alternativa a la cirugía radical.

Asimismo, entre las últimas novedades de dermocosmética destacan los tratamientos mínimamente invasivos, tales como Bio-Alcamid, endoprótesis que permiten suplir carencias de tejido sin necesidad de quirófano, sólo inyectándolas, el aumento de mama sin cirugía, indicado para pequeñas correcciones, o un nuevo tratamiento para las arrugas con efecto tensor, Skin Renu, que puede llevar a cabo el paciente en su propia casa.

Y, siempre, con la garantía de calidad y seguridad en los tratamientos que ofrecen grandes compañías como Lumenis, líder mundial en el campo del láser y el IPL, entre otras.

GRUPO MEDIFORM
Doctor Trueta, 46, local - 08005 BARCELONA
www.mediform.com
e-mail: informacion@mediform.com



This is Google's cache of <http://www.develop4u.com/smallcapfn/FILES/srgl.htm>. Google's cache is the snapshot that we took of the page as we crawled the web. The page may have changed since that time. Click here for the current page without highlighting. To link to or bookmark this page, use the following url: http://www.google.com/search?q=cache:OpwtfM8z3IJ:www.develop4u.com/smallcapfn/FILES/srgl.htm+Surgilight+vilitigo+OR+XeCl+OR+cool+OR+cooling+*22spencer*22&hl=en&ie=UTF-8

Google is not affiliated with the authors of this page nor responsible for its content.

These search terms have been highlighted: **surgilight vitiligo spencer**



Corporate Headquarters

<[endif]-->

SURGILIGHT INC.

12001 Science Dr., Suite 140

Orlando, FL 32826

Phone: (407) 482-4555 o FAX: (407) 482-0505

www.surgilight.com

INVESTMENT PROFILE

July 10, 2000 - August 28, 2000



**Surgilight Receives FDA Clearance for the EX-308 Excimer Laser for
the Treatment of Psoriasis**



OVERVIEW


Surgilight (Small Cap FNBB: SRGL), a world leader of IR-laser for vision correction, owns 4 US pending patents for new laser technologies in "Presbyopia Reversal" which has a

potential US market over \$150 billion. In addition, it operates 21 Laser Eye Centers worldwide for recurring incomes based on royalty fees. The Company also developed a new laser for psoriasis treatment which is expected to obtain the FDA approval within few weeks. The Company has recently signed a joint venture agreement with MircraUS for European CE-mark approval and marketing. The Company's products model IR-3000, and IR-5000 are the world's first systems for vision correction using its new IR laser technologies and are currently under the clinical trials. In addition to the Laser Eye Center incomes, the Company also gains incomes from its two spin-off divisions in night vision systems and cosmetic centers. As the results of over 10 years R&D, the Company has been the pioneer and inventor of scanning laser and advanced IR lasers. The Company is currently applying for a listing on the Nasdaq NM.

Dr. J.T. Lin, the founder of **Surgilight** and the inventor of the scanning laser for vision correction (1994), and the solid-state UV-laser for PRK (1992), was also the founder of LaserSight (1991) and is a former Associate Professor (1987-91) at the Univ. of Central Florida Laser Center. Dr. Lin has more than 80 publications and books.

Lasers for vision correction have been the most important and largest market for all medical applications that use lasers. Within this vision correction market **Surgilight** owns the patent-pending technology for presbyopia correction. Presbyopia correction has a U.S. market of over \$150 billion and a worldwide market of over \$1.5 trillion. **Surgilight** expects to have a minimum market penetration of 15% - 20% via its sales of new devices and the income from royalty fees charged to the surgeons.

The Company's strategy is to focus on the recurring revenue and income from The royalty fee of new technology and from



SRGL

[Get Latest Quote, News and Chart](#)

COMPLETE RATIO REPORT

BALANCE SHEET

LIQUIDITY AND CAPITAL RESOURCES

The total current assets of the Company increased to \$2,553,000 as of March 31, 2000, compared with \$1,542,000 of the end of March, 1999. This increase in current assets is mainly attributed to the additional paid in capital of \$1,232,000 from an accredited investor. The Company expects to obtain more proceeds from accredited or Institutional investors in the second quarter of

laser centers operation. The Company, however, will continue to develop new products for new markets mainly outside the U.S. These new products shall include diode lasers for microsurgery, UV laser for skin treatments, infrared lasers for vision correction and the Company's patent pending new technology for presbyopia correction. The Company believes that it is the only company has the in-house technologies to support and/or up-grade the systems used in its Centers. The Company's start-up system cost for its international Laser Centers, in which systems were made by the Company, is only 30% of that of its competitors which purchase systems from others. However, there can be no assurance that the Company will be successful in operating these Laser Centers without suffering future competitions from those that may also operate Centers in and also own the in-house technologies.

The presbyopia worldwide potential procedure income is estimated to be over \$1,500 billion, since almost 100% of the worldwide population for ages older than 45 will become presbyopia. This estimation is based upon the worldwide population of 900 million (15%) who are presbyopia and an average procedure fee of \$2,000 per patient. The US presbyopia population is approximately 40 million which also representing a potential procedure income of about \$160 million based upon a fee of \$2,000 per eye. The current treatments for presbyopia including implants and diamond-knife incision which have drawbacks of being a complex surgical procedure and require a lot of the surgeon's experience. Another method is to use a Ho:YAG laser for monovision correction, a clinical trial system made by Sunrise Technology. This method however can only treat one eye for near view and requires the second eye un-treated to see far. Strictly speaking the Ho:YAG method is not a presbyopia correction but only correct hyperopia in one eye.

The Company's new method of using lasers for presbyopia

2000. The Company will use this addition funding to continue its on-going clinical trials and to expand its international Laser Centers.

The net cash increased from \$577,594 on December 31, 1999 to \$1,334,823 on March 31, 2000 mainly due to the addition paid in capital of \$1,232,000. The Company anticipates that its current cash, cash equivalents, as well as anticipated cash flows from operations and additional capital contribution from private placements, will be sufficient to meet its working capital and capital equipment needs at least through the next twelve months. The Company expects to raise additional funds via private placements during the second quarter of 2000.

OTHER INFORMATION (Clinical Trials and New Products Up-date)

1. The Company is currently conducting clinical trials at Caracas, Venezuela for the treatment of presbyopia patients using the Company's patent pending technology. The clinical results (for 15 cases) performed by Drs. Perrasa and Martinez at the Company's Microsurgical Laser Center at Caracas, Venezuela, were reported at the 1999 Fall World Refractive Surgery Symposium (October 21-23, Orlando, FL). A second paper for the results of 21 cases with follow-up longer than 8 months was submitted for presentation in the Summer World Refractive Surgery Symposium (July 21-23, Miami, FL). The Company plans to open several more Laser Centers in Latin America countries for the LASA procedure using its patent pending device.

2. The Company has another on-going clinical trial at Mt. Sinai Hospital, New York, using a UV-laser for the treatment of Psoriasis and **vitaligo** which affect a worldwide population of about 2% or 100 million, according to the report by Dr. **Spencer** at Mt. Sinai Hospital, NY. Clinical results were submitted for

reversal has advantages of a being precise, fast and simple procedure which does not require surgeon's experience. The new procedure will be less complications and more stable, less regression than the mechanical, non-laser methods. The Company is currently conducting clinical trials in Venezuela and the results was presented at the 1999 Fall World Refractive Surgery Symposium (Orlando, Oct. 24-26, 1999). The Company believes that it is the first and the only company offering this new procedure which is now limited to the international market prior to the US approval. The Company currently has three pending patents relating to the new procedure and new IR- laser technologies. However, there can be no assurance that the Company will be successful in protecting its proprietary technologies or in completing its market approval in the U.S. on schedule. (See ITEM 5 of Part II in this filing for greater details).

The Company believes that it is the only company currently owning both the ultraviolet (UV) and infrared (IR) laser technologies for vision corrections. For vision corrections using UV lasers, there are several existing patents which may prohibit our sales of the UV lasers without obtaining a license. The Company has three pending patents for the use of IR lasers which has the potential of replacing the existing UV lasers currently used by most of its competitors including Visx, Summit, Bausch & Lomb, LaserSight, Nidek, Schwind and Meditec. The IR lasers, the Company believes, will be have less mutagenic effects and safer than the UV lasers which may have potential risk of long-term biological complications. However, prior to the market approval in US the Company's new products will be limited to international sales. The Company believes that its Infrared (IR) lasers for vision corrections will be protected by its proprietary technology and its pending patents. In addition, the users of the Company's IR lasers will not have to pay the license fee or royalty fee which are required for the use of UV lasers. Currently, the UV laser royalty fee in the U.S. is about \$250 per case paid to the patent

the application of a 510K marketing approval.

3. The Company will continue its R&D for several new products including the UV-laser for skin treatment (market approval is expected in 2000, if a 510K approval can be completed) and the new infrared lasers for microsurgery and vision correction, the models IR-3000, IR-3001 and IR-2000 which will take several years for the U.S. market approval. International marketing for these new products, however, will start during the early part of year 2000, in addition to our existing UV lasers market. The Company had signed an agreement with MicraUS for a joint venture in UK to manufacture and market its products in Europe. However there can be no assurance that the Company will be successful in completing the clinical trials and obtaining necessary approvals as scheduled.

owners Visx and Summit. The UV laser manufacturers also need to pay the IBM-patent fee of about 3%-7% of their sale price. Without paying these fees, the Company believes that its IR lasers will have advantages in both profit margin and the market competitions. However, there can be no assurance that the Company will be successful in protecting its proprietary and pending patents to avoid these license and or royalty fees.

The medical laser industry is new and needs the approval from FDA prior to marketing in the U.S. Our competitors are significantly larger in their financial condition and several of them have now received FDA approval in vision correction using excimer lasers. We will also face increased competition from manufacturers of vision correction lasers and from companies operating laser centers in the U.S. and internationally. The Company's medical lasers will need either 510(K) approval, which takes only 6-12 months, or PMA and IDE approvals which may take a few years to complete prior to the market approval in the U.S. Prior to these market approvals, the Company's medical products will be limited to international sales and these products need to be manufactured outside US. The Company believes that its UV-laser for dermatology uses and the waterjet system (made by VisiJet and marketed by the Company in certain countries) will only need 510(K) approval. The other new products of the Company will require PMA approval. However there can be no assurance that the Company will be successful in obtaining these market approvals as scheduled. The Company has recently submitted a 510(K) application for its UV-308 laser for the treatment of skin diseases including psoriasis and **vittiligo**.

The Company's Plantation Eye Center currently has over 20 surgeons using the excimer laser facility. These existing surgeons however may leave the Company if they decide to operate their own Center or join other Centers offering a better term than the Company. All of these factors may influence our

RESULTS OF OPERATIONS

Revenues for the first quarter ended March 31, 2000 increased 61% to \$761,000 from \$472,000 for the same period of 1999. The growth of revenues and operation incomes are attributed to the Company's growth in system sales and procedure income from the Laser Centers.

For the first quarter ended March 31, 2000, the Company reported an operation income of \$20,000, excluding the facility depreciation of \$50,000. The net loss (after the facility depreciation) of the first quarter of 2000 was \$30,000 or \$0.001 per share, compared to a net loss of \$16,000 or \$0.001 per share for the same period of 1999.

The total revenue for the first quarter is attributed to the Company's two divisions, the Laser Eye Centers and sales of systems. In addition, the Company also obtained incomes from Advanced Marketing Technology for the Cosmetic Laser Centers and EMX for night vision products. In this quarter, the Company was established two more Eye Laser Centers in Asian countries and now has a total of 20 Laser Eye Centers.

Operating expenses for the first quarter of 2000 was \$481,000, compared with \$411,000 of the same period of 1999. The increase in operating expenses is proportional to the total revenue and increased sales effort. In addition, R&D costs and clinical trials costs will continue to increase in the future quarters to support our focus on the Company's new infrared lasers and the related ongoing clinical trials in Latin America, Europe and US.

systems sales and income from laser centers. Accordingly, our past results may not be useful in predicting our future results.



LASIK



LASER EYE CENTERS

Surgilight currently operates 18 Laser Eye Centers (LEC) worldwide using the most advanced systems:

- Scanning Lasers for international hospitals out-patient centers
- VISX Lasers for US Centers. For dates of **Visx physician certification courses** to be held at our Plantation Florida Center go to [VISX](#).
- A **VISX PHYSICIAN CERTIFICATION COURSE** will be held **TUESDAY, JULY 18, 2000** (to coincide with ISRS Miami meeting) will be held at:

The total current assets of the Company increased to \$2,553,000 as of March 31, 2000, compared with \$1,542,000 of the end of March, 1999. This increase in current assets is mainly attributed to the additional paid in capital of \$1,232,000 from an accredited investor. The Company expects to obtain more proceeds from accredited or Institutional investors in the second quarter of 2000. The Company will use this addition funding to continue its on-going clinical trials and to expand its international Laser Centers.

The Company hopes to receive FDA clearance for the EX-308 laser for the phototherapy treatment of psoriasis and related skin disorder soon. In preparation for this clearance, the Company appointed Claude S. Burton, M.D., Associate Professor of Medicine and Director of the Laser Clinic at Duke University Medical Center, as the Medical Advisor.

The inventory for the third quarter remains about the same as that of the third quarter. Account receivable increase from \$232,000 in second quarter to \$598,000 in the third quarter because of the financing program offered to one User in Korea and the deposits from two Eye Centers in China, where payments are due system installation. The current assets on September 30, 1999 increases about \$100,000 compared to the second quarter end because of the net income.

R&D costs and clinical trials costs will continue to increase in future to support our focus on the Company's new infrared lasers and the related ongoing clinical trials in Venezuela and Mt. Sinai Hospital in New York City. The Company's strategy is to focus on the recurring revenue and income from the laser centers operation. The Company, however, will continue to develop new products for new markets mainly outside the U.S. These new products shall include diode lasers for microsurgery, infrared laser for vision correction and the Company's patent pending new technology for presbyopia correction. The Company's

**SURGILIGHT LASER CENTER, PLANTATION, FL
33324**

(30 minutes north of Miami meeting site)

(954) 370-3352 Telephone

(954) 370-2262 Fax

Contact person: Georgie Refner, RN

Call for information and registration process (limited class size). For more

information visit: www.isrs.com.

Our International LECs now offer clinical trials for the new Laser Presbyopia Reversal (LPR) procedure using the Company's patent pending technologies. Clinical studies in the US will begin in the near future.

Our LEC at Ft. Lauderdale-Plantation is a state-of-the-art facility with over 25 certified MDs providing highest quality LASIK procedures.

For Surgeons interested in joining our Centers, please call (407)482-4555 or fax:(407)482-0505

For patient **complimentary** consultation, please contact any of the following doctors in your local area or call Georgann at (954)370-3352.

Plantation Florida Laser Eye Center Surgeons

Richard Beckman, MD	Ray P. Galitis, MD (Medical Director)
---------------------	---------------------------------------

Wayne Bizer, DO	Lee I. Klein, MD
-----------------	------------------

Randy Burks, MD	Andrew Logan, MD
-----------------	------------------

David B. Cano, MD	Paul W. Maurer, MD
-------------------	--------------------

Leon Cohn, MD	Paul Rosenblum, MD
---------------	--------------------

Jorge Camacho, MD	Stanley M. Rous, MD
-------------------	---------------------

clinical trials shall include two infrared laser systems for microsurgery and presbyopia and one UV laser for skin treatment, where clinical trials will be conducted both in the US and internationally. The Company has on-going clinical trials at Caracas, Venezuela for laser presbyopia reversal and at Mt. Sinai Hospital, New York, for UV-laser skin treatments. The Company plans to start more clinical sites in US and internationally within the next few months. The revenue from system sales is not expected to grow as fast as revenue from the centers until new products are developed or approved for marketing.

Noel L. Elgut, MD	Douglas B. Shapiro, MD
Marc Feldman, MD	David R. Simon, MD
Kenneth Kasten, MD	Jacqueline E. Smith, MD
Richard S. Kalski, MD	Russell Wolfe, MD
Hassan Tavakkoli, DO	Taylor G. Poole, MD
Luis D. Villani, MD	Manuel A. Airala, MD
Maged S. Habib, MD	Richard P. Margolies, MD



Search Results

SURGILIGHT INC

Ticker: SRGL Exchange: OTCBB

Total Number of SEC Filings Found **35**

Add this company to your Watchlist SIC Code: 6770

<u>FORM TYPE</u>	<u>FORM DESCRIPTION</u>	<u>DATE FILED</u>	<u>SIZE (KB)</u>
<u>10-Q</u>	Quarterly Report	7/28/2000	34
<u>8-K</u>	Current Report	7/24/2000	7
<u>DEF 14A</u>	Definitive Proxy Statement	6/2/2000	35
<u>10-Q/A</u>	Amended Quarterly Report	5/15/2000	37
<u>10-Q</u>	Quarterly Report	4/28/2000	41
<u>8-K</u>	Current Report	4/5/2000	364
<u>10-K</u>	Annual Report	3/31/2000	124
<u>8-K</u>	Current Report	3/31/2000	5
<u>10KSB</u>	Annual Report	3/30/2000	4
<u>8-K</u>	Current Report	1/25/2000	5
<u>8-K</u>	Current Report	1/24/2000	22

<u>DEF 14C</u>	Definitive Information Statement	1/18/2000	17
<u>10QSB</u>	Quarterly Report	11/22/1999	34
<u>8-K</u>	Current Report	11/8/1999	3
<u>SC 13G/A</u>	Amended Statement of Beneficial Ownership	10/8/1999	8
<u>10QSB/A</u>	Amended Quarterly Report	8/12/1999	33
<u>10QSB</u>	Quarterly Report	8/2/1999	28
<u>8-K/A</u>	Amended Current Report	5/25/1999	22
<u>10QSB</u>	Quarterly Report	5/24/1999	24
<u>SC 13D</u>	General Statement of Beneficial Ownership	4/12/1999	10
<u>SC 13D</u>	General Statement of Beneficial Ownership	4/12/1999	10
<u>SC 13D</u>	General Statement of Beneficial Ownership	4/12/1999	10
<u>SC 13D</u>	General Statement of Beneficial Ownership	4/12/1999	9
<u>SC 13D</u>	General Statement of Beneficial Ownership	4/12/1999	10
<u>SC 13D</u>	General Statement of Beneficial Ownership	4/12/1999	10
<u>4</u>	Statement of Changes of Beneficial Ownership	4/12/1999	11
<u>SC 13D</u>	General Statement of Beneficial Ownership	4/12/1999	10
<u>8-K/A</u>	Amended Current Report	4/9/1999	6
<u>SC 14F1</u>	Statement of Re Change in Majority of Directions	4/7/1999	18
<u>8-K</u>	Current Report	4/7/1999	106
<u>10KSB</u>	Annual Report	2/12/1999	57
<u>S-8</u>	Registration Statement	2/12/1999	21
<u>5</u>	Annual Statement of Changes in Beneficial Ownership	1/6/1999	11
<u>10QSB</u>	Quarterly Report	1/5/1999	18
<u>10-12G/A</u>	Amended Registration Statement	11/27/1998	142
<u>10-12G</u>	Registration Statement	9/16/1998	140
<u>3</u>	Initial Statement of Beneficial Ownership	9/16/1998	7
<u>SC 13D</u>	General Statement of Beneficial Ownership	9/16/1998	10

Officers and Directors

EXECUTIVE OFFICERS		
	Age	Position
Lin, J. T., Ph.D.	52	Chairman of the Board, Treasurer, President, Chief Executive Officer
Shea J, Timothy	43	COO
Sir, Rachel, CPA	53	CFO
Hwang, Ming-Yi, Ph.D.	45	VP of Research and Development
Reffner, Richard	53	VP of Laser Eye Center

BOARD OF DIRECTORS		
	Age	Position
Lin, J. T., Ph.D.	52	Chairman of the Board, Treasurer, President, Chief Executive Officer
Shea J, Timothy	43	COO
Reffner, Richard	53	VP of Laser Eye Center
Yuan, J. S. Ph.D.	42	Professor, UCF Board Member
Chow, Lee, Ph.D.	50	Professor, UCF Board Member
Ajayl, Richard, Ph.D.	52	Professor, UCF Board Member

Significant Developments

Tuesday, August 15, 2000

09:47 ET **Surgilight** Receives FDA Clearance for the EX-308
Excimer Laser for the Treatment of Psoriasis (BW)

July 31, 2000

- **Surgilight** Reports Second Quarter 2000 Results Showing 24% Revenue Growth - *Business Wire* - 9:55 am

July 28, 2000

- **SURGILIGHT INC** - Quarterly Report (SEC form 10-Q) - *EDGAR Online* - 1:42 pm

Wednesday, July 26, 2000

08:08 ET MAS Capital Begins Direct Public Offering in New York (BW)

Monday, July 24, 2000

12:20 ET **Surgilight** Presents the Clinical Results at the World Refractive Surgery Symposium for its New Laser for Presbyopia (BW)

11:39 ET Serengeti Eyewear, Oakley and Pharmos Are First-Half Performance Leaders in OptiStock.com's Rankings of Vision Care Stocks (BW)

Thursday, July 20, 2000

09:54 ET OTCNetStocks.com: Executives of **Surgilight** are featured on an exclusive interview with OTCNetStocks.com (MT)

09:53 ET **Surgilight** Secures \$3 Million in Corporate Fund Raising Program (BW)

Tuesday, July 18, 2000

11:15 ET **Surgilight** Concludes the Joint Venture with MicraUSA, Inc. in the United Kingdom (BW)

Wednesday, July 12, 2000

12:31 ET **Surgilight** Announces a Marketing Alliance with a Chinese Medical Equipment Manufacturer (BW)

Monday, July 10, 2000

16:11 ET **Surgilight** Asserts the Lawsuit Brought by PhotoMedex is Baseless and Without Merit (BW)

12:17 ET PhotoMedex Sues **Surgilight** For Misappropriation Of Trade Secrets (BW)

Thursday, July 06, 2000

09:48 ET **Surgilight** Announces Plans to Buy Back Stock (BW)

Wed Jul 12, 2000

- [Surgilight Announces a Marketing Alliance with a Chinese Medical Equipment Manufacturer](#)
Business Wire - 12:16 PM EDT

Mon Jul 10, 2000

- [PhotoMedex Files Suit Vs. Surgilight](#) Dow Jones - 04:18 PM EDT

- [Surgilight Asserts the Lawsuit Brought by PhotoMedex is Baseless and Without Merit](#) Business Wire - 03:56 PM EDT

Thu Jul 06, 2000

- [Surgilight Announces Plans to Buy Back Stock](#) Business Wire - 09:33 AM EDT

June 26, 2000

Surgilight Inc. announced that it has submitted a new patent application for presbyopia correction using infrared lasers and has opened the first Laser Eye Center in Vietnam. In addition, the Company has expanded its cosmetic mobile laser centers (CMLC) from three in Florida (with 45% control) to the fourth in Venezuela (with 100% control). The Company has a plan to operate more than 50 CMLC in the next five years.

May 16, 2000

Surgilight Inc., announced today that it will introduce the world's first IR-laser for presbyopia treatment at the American Society of Cataract and Refractive Surgery (ASCRS) to be held at Boston this week. In addition the Company will also present an up-date of its new infrared (IR) lasers at the Refractive Technology Forum scheduled for May 21st at the Ritz Carlton Hotel in Boston during the ASCRS Conference.

April 18, 2000

Surgilight, Inc. today announced financial results for the first quarter ended March 31, 2000. The first quarter 2000 revenue shows an increase of 61 % over the same period in 1999. The Company also announced the appointment of Clause Burton, M.D., Associate Professor at Duke University, as its Medical Advisor. Revenues for the first quarter ended March 31, 2000 increased 61% to \$761,000 from \$472,000 for the same period of 1999. The growth in revenue and operation income is attributed to the Company's growth in system sales and procedure income from the Laser Centers owned by the

Company.

March 28, 2000

Surgilight Inc. announced that Ms. Deborah S. Adkins has been hired as the new Chief Financial Officer of the Company and will begin her responsibilities as a part-time employee until further notice.

March 16, 2000

Surgilight Inc. announced that the Company currently has three (3) patents pending regarding the laser techniques for presbyopia correction. These patents were filed in November of 1998, May of 1999, and September of 1999. These pending patents cover a broad range of wavelengths for the correction of presbyopia, and innovative laser beam reshaping techniques.

March 6, 2000

Surgilight Inc. announced that it has signed a Letter of Intent with MicraUSA to form a Joint Venture in the United Kingdom to assemble and market the Escan, IR-3000, and IR-3001 laser systems. MicraUK, Ltd., is a wholly owned subsidiary of MicraUSA. MicraUK gained ISO 9002 and EN 46002 certification for its quality system in 1995 and it is fully accredited for European CE marking.

February 24, 2000

Surgilight Inc. announced that it has submitted an Investigational Device Exemption (IDE) to the Food and Drug Administration (FDA) for the new procedure of Laser Presbyopia Reversal using its patent pending technology. The Company also expects to obtain the IRB approval from Mt. Sinai Hospital in New York for this new IDE clinical trial soon.

February 14, 2000

Surgilight Inc. announced that it has concluded a Letter of Intent to acquire IR-Vision, Inc. (San Jose, CA) for approximately \$3.2 million all paid by **Surgilight's** common stock. The Company is also negotiating with HOYA, Inc. (Japan) for laser presbyopia correction new technology. According to the acquisition terms, the Company will acquire all assets and shares of IR Vision, Inc. that was 40% owned by HOYA and 60% owned by the founders of IR Visions and others.

February 1, 2000

Surgilight Inc. announced that it has submitted an application for the NASDAQ National Market listing. The Company believes that it is fully qualified and fits all the criteria necessary for inclusion on the NASDAQ National Market.

January 26, 2000

Surgilight, Inc. announced that it has concluded an Agreement with VisiJet, Inc. (Irvine, CA) for an exclusive marketing license in certain countries for VisiJet's patented waterjet devices. They are expecting FDA approval within a few months. According to the Agreement with VisiJet, the Company will have the exclusive, royalty-free license, to market in Central America, South America, Mexico, People's Republic of China, Hong-Kong and Taiwan for the new HydroKeratome and Pulsatome devices patented and made by VisiJet for ophthalmic applications in vision correction and cataract surgery.

January 20, 2000

Surgilight Inc. announced that it held a special Board of Directors meeting to approve the spin off of two divisions not associated with the Company's core technology. The Cosmetic Mobile division (AMT) and the non-medical Thermal Imaging division (EMX) were recently spun off allowing the company to focus on the development of two new infrared (IR) laser based systems for vision correction including LASIK and presbyopia procedures. After the spin off, the Company will still collect a portion of the incomes from these two divisions.

January 20, 2000

Surgilight Inc. announced that Mr. Timothy J. Shea has been hired as Senior Vice President and Chief Operating Officer and appointed as Secretary of the Board of Directors.

WEBSITE INFORMATION

Copies of company press releases, SEC filings, current price quotes and stock charts may be found on the website <http://www.surgilight.com>

To SUBSCRIBE to our **FREE** Newsletter and gain total access of our upcoming profiles, please enter your email address:

Why Join?

Disclaimer

This profile published by Small Cap FN is an independent electronic publication providing information and factual analysis on selected companies. All statements and expressions are the opinion of Small Cap FN and are not meant to be either investment advice or a solicitation or recommendation to buy, sell, or hold securities. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Small Cap FN is not a registered investment advisor or a broker dealer. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Profiles rely on information provided by the featured Companies and/or Edgar filings. While Small Cap FN believes its sources to be reliable, associates of Small Cap FN, or any affiliated parties make no representation or warranty as to the accuracy of the information provided. Readers should not rely solely on the information contained in this publication, but should consult with their own independent tax, business and financial advisors with respect to any investment opportunity, including any contemplated investment in the advertised Company.

Factual statements in this publication are made as of the date stated and are subject to change without notice. Small Cap FN is not responsible for any claims made by the Company. We have prepared this report, drawing upon a range of public news, the company's website and information from sources in the industry, as well as data and opinions provided by the company. Prior to issuing this report, the Company reviewed and approved the contents in writing hereof. Small Cap FN has not independently verified the Company's representations. Any opinions expressed in this report are statements of judgment as of the date of publication. We urge readers to carefully verify all presentations within the report independently. The receipt of this publication shall not create, under any circumstances, any implication that there has been no change in the affairs of the company profiled since the date of review. This advertisement does not provide an analysis of the Company's financial position. Small Cap FN of this advertisement has been paid 5,000 six-month restricted shares of SRGL with a 300 shares lockup period max a day to sell on the open market,

to company account, by **SurgeLight** Inc., and we do not hold any positions in this stock, for the preparation and electronic dissemination of this report. This should be viewed as a potential conflict of interest. Furthermore, associates of Small Cap FN may have stock positions on profiled companies from time to time. We may profit in the event the shares of the Company profiled by us increase in value. These positions may be liquidated from time to time even after we have made positive comments regarding the Company. The receipt of this information constitutes your acceptance of these terms and conditions.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS: Except for historical information contained herein, the statements on this website and newsletter are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results in the future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product price volatility, product demand, market competition and risk inherent in the companies operations. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ``anticipate," ``estimate," ``expect," ``project," ``intend," ``plan," ``anticipate", "guess", "think", "hear", "suggest", "believe," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.

As a suggestion, "Never, ever, make an investment based solely on what you read in an online newsletter or Internet bulletin board, especially if the investment involves a small, thinly-traded company that isn't well known," said Nancy M. Smith, Director of SEC's Office of Investor Education and Assistance. "Assume that the information about these companies is not trustworthy unless you can prove otherwise through your own independent research. " "Internet Fraud" is available on the SEC's Web Site, at <http://www.sec.gov/consumer/cyberfr.htm>.

<u>Hot Stock Pick #1 (short)</u>	<u>Hot Stock Pick #2 (long)</u>
<u>Hot Stock Pick #3 (long)</u>	<u>Hot Stock Pick #4 (short)</u>

 GetFAT!